| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 5841 | 2019 |
| Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes T Ninomiya, V Perkovic, BE De Galan, S Zoungas, A Pillai, M Jardine, ... Journal of the American Society of Nephrology 20 (8), 1813-1821, 2009 | 1165 | 2009 |
| Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ... The Lancet 390 (10105), 1888-1917, 2017 | 1028 | 2017 |
| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ... The lancet Diabetes & endocrinology 7 (11), 845-854, 2019 | 871 | 2019 |
| Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials HJL Heerspink, T Ninomiya, S Zoungas, D de Zeeuw, DE Grobbee, ... The Lancet 373 (9668), 1009-1015, 2009 | 559 | 2009 |
| Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial J Lv, H Zhang, MG Wong, MJ Jardine, M Hladunewich, V Jha, ... Jama 318 (5), 432-442, 2017 | 521 | 2017 |
| Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease SC Palmer, SD Navaneethan, JC Craig, DW Johnson, M Tonelli, AX Garg, ... Annals of internal medicine 153 (1), 23-33, 2010 | 480 | 2010 |
| Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference CM Clase, JJ Carrero, DH Ellison, ME Grams, BR Hemmelgarn, ... Kidney international 97 (1), 42-61, 2020 | 444 | 2020 |
| Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease Sharp Collaborative Group American heart journal 160 (5), 785-794. e10, 2010 | 430 | 2010 |
| Canagliflozin slows progression of renal function decline independently of glycemic effects HJL Heerspink, M Desai, M Jardine, D Balis, G Meininger, V Perkovic Journal of the American Society of Nephrology 28 (1), 368-375, 2017 | 406 | 2017 |
| Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials C Baigent, JR Emberson, R Haynes, WG Herrington, P Judge, ... The Lancet 400 (10365), 1788-1801, 2022 | 391 | 2022 |
| Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta‐analysis T Toyama, BL Neuen, M Jun, T Ohkuma, B Neal, MJ Jardine, ... Diabetes, Obesity and Metabolism 21 (5), 1237-1250, 2019 | 330 | 2019 |
| Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results … KW Mahaffey, MJ Jardine, S Bompoint, CP Cannon, B Neal, ... Circulation 140 (9), 739-750, 2019 | 302 | 2019 |
| The relationship between proteinuria and coronary risk: a systematic review and meta-analysis V Perkovic, C Verdon, T Ninomiya, F Barzi, A Cass, A Patel, M Jardine, ... PLoS medicine 5 (10), e207, 2008 | 302 | 2008 |
| Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS Program BL Neuen, T Ohkuma, B Neal, DR Matthews, D De Zeeuw, KW Mahaffey, ... Circulation 138 (15), 1537-1550, 2018 | 278 | 2018 |
| The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics MJ Jardine, KW Mahaffey, B Neal, R Agarwal, GL Bakris, BM Brenner, ... American journal of nephrology 46 (6), 462-472, 2018 | 264 | 2018 |
| Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis SC Palmer, L Di Micco, M Razavian, JC Craig, V Perkovic, F Pellegrini, ... Annals of internal medicine 156 (6), 445-459, 2012 | 262 | 2012 |
| Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis W Hou, J Lv, V Perkovic, L Yang, N Zhao, MJ Jardine, A Cass, H Zhang, ... European heart journal 34 (24), 1807-1817, 2013 | 261 | 2013 |
| Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial MJ Jardine, T Ninomiya, V Perkovic, A Cass, F Turnbull, MP Gallagher, ... Journal of the American College of Cardiology 56 (12), 956-965, 2010 | 260 | 2010 |
| Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis C Arnott, Q Li, A Kang, BL Neuen, S Bompoint, CSP Lam, A Rodgers, ... Journal of the American Heart Association 9 (3), e014908, 2020 | 257 | 2020 |
Vlado PerkovicDean of Medicine, University of New South Wales; Professorial Fellow, The George InstituteVerified email at george.org.au
